Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended	9 Months Ended
	Oct. 30, 2023	Feb. 28, 2023	Sep. 30, 2024	Sep. 30, 2023	Jun. 28, 2024	Dec. 31, 2023
Commitments And Contingencies Disclosure [Line Items]
CVR derivative liability			$ 4,900			$ 4,722
Purchase of property and equipment			2,380	$ 6,193
Maximum
Commitments And Contingencies Disclosure [Line Items]
Investment obligation amount					$ 4,200
Percentage of equity interest					18.90%
Property and Equipment
Commitments And Contingencies Disclosure [Line Items]
Purchase of property and equipment			1,600
Research and Development
Commitments And Contingencies Disclosure [Line Items]
Committed to allocate			$ 21,300
Contingent Value Rights Agreement
Commitments And Contingencies Disclosure [Line Items]
Percentage of excess cash on dispositions net			100.00%
Excess amount retained from net proceeds related to disposition of assets			$ 1,000
Percentage of excess preapproved costs			100.00%
Distribution to CVR holders from asset sale proceeds		$ 200
Long-term CVR derivative liability		$ 4,500
CVR derivative liability						$ 4,700
Contributions closing payable amount	$ 1,100
Remaining outstanding balance			$ 0
F351 \| Gyre Pharmaceuticals \| Submission of the New Drug Application
Commitments And Contingencies Disclosure [Line Items]
Obligation to pay in exchange for the intellectual property rights			4,700
F351 \| Gyre Pharmaceuticals \| NDA Passes the NMPA's Review and Inspection
Commitments And Contingencies Disclosure [Line Items]
Obligation to pay in exchange for the intellectual property rights			1,200
F351 \| Gyre Pharmaceuticals \| NMPA's Approval of the NDA
Commitments And Contingencies Disclosure [Line Items]
Obligation to pay in exchange for the intellectual property rights			$ 7,100